• Careers
  • Investors
  • News
  • Partnering
  • Contact Us
 
  • Home
  • Our Products
    • Recent Products
    • Consumer Products
    • Medical Devices & Diagnostics
    • Prescription Products
    • Product Coupons
  • Our Caring
    • Our Stories
    • Our Giving
    • Our Responsibility
    • Protecting Our People
    • Company Initiatives
  • Our Company
    • Our Credo Values
    • Our Management Approach
    • Our Citizenship
    • Corporate Governance
    • Company Structure
    • Our People & Diversity
    • Company Publications
    • Our History
  • News
    • All News
    • Corporate News
    • Product And Operating Company News
    • Financial News
    • Media Contacts
    • All News Archive
  • Text Size
  • Text Only
  • Email to a Friend
  • Printer Friendly
  • RSS

All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | .... 39 Next >
FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

June 21, 2012

Dr. Victor Ambros and Dr. Gary Ruvkun Win 2012 Dr. Paul Janssen Award for Biomedical Research for Discovery of MicroRNAs

June 19, 2012

Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results

June 18, 2012

Janssen Submits Additional Marketing Applications for ZYTIGA® In the U.S. and European Union

June 15, 2012

Johnson & Johnson Announces Completion of Synthes Acquisition

June 14, 2012

Johnson & Johnson Receives U.S. Regulatory Clearance for Synthes Acquisition; Closing Date for Transaction Set

June 12, 2012

< Prev | | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | .... 39 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Employees
  • Careers
  • Investors
  • News
  • Partnering
  • Contact Us
Johnson & Johnson
  • Home
  • Our Products
  • Our Caring
  • Our Company
  • All News
  • Corporate News
  • Product And Operating Company News
  • Financial News
  • Media Contacts
  • All News Archive
  • Text Size
  • Graphic Version
  • Email to a Friend
  • Printer Friendly
  • RSS

All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | .... 39 Next >
FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

June 21, 2012

Dr. Victor Ambros and Dr. Gary Ruvkun Win 2012 Dr. Paul Janssen Award for Biomedical Research for Discovery of MicroRNAs

June 19, 2012

Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results

June 18, 2012

Janssen Submits Additional Marketing Applications for ZYTIGA® In the U.S. and European Union

June 15, 2012

Johnson & Johnson Announces Completion of Synthes Acquisition

June 14, 2012

Johnson & Johnson Receives U.S. Regulatory Clearance for Synthes Acquisition; Closing Date for Transaction Set

June 12, 2012

< Prev | | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | .... 39 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •